KRAS and non-small cell lung carcinoma: Moreover, developing targeted drugs for other point mutations within the KRAS gene is at a bottleneck, with approximately 70% of KRAS-mutant Non-small cell lung cancer (NSCLC) patients with non-G12C point mutations still lacking available therapeutic inhibitors [7].